年間 6 号発行
ISSN 印刷: 0743-4863
ISSN オンライン: 2162-660X
IF:
2.7
5-Year IF:
3.6
Immediacy Index:
0.8
Eigenfactor:
0.00023
JCI:
0.39
SJR:
0.42
SNIP:
0.89
CiteScore™::
5.5
H-Index:
79
Indexed in
Colloidal Carriers: A Rising Tool for Therapy of Tuberculosis
Get access
要約
Tuberculosis (TB) is the second most deadly infectious disease, caused mainly by M. tuberculosis in humans, usually affecting the lungs; it also attacks other parts of the body. The design of novel antibiotics attempts to overcome drug resistance, to shorten the treatment course, and to reduce drug interactions with antiretroviral therapies. Overcoming technological drawbacks of these therapeutic agents as well as improving the effectiveness of the drugs by targeting the infection reservoirs remain the central aims of pharmaceutical technology. In this framework, colloidal carriers appear as one of the most promising approaches for the development of more effective and compliant medicines by releasing the drugs slowly over prolonged time periods and reducing the current costs of treatment. Due to unique physicochemical properties (ultrasmall and controllable size, large surface area to mass ratio, high reactivity, and functionalizable structure) of colloidal carriers, they can facilitate the administration of antitubercular drugs, thereby overcoming some of the limitations in traditional antitubercular therapeutics. In recent years, encapsulation of antitubercular drugs in colloidal carrier systems is emerging as an innovative and promising alternative with enhanced therapeutic effectiveness and reduced undesirable side effects of the encapsulated drugs. The present review aims to describe the current conventional as well as combination drug therapy with special consideration towards the emerging role of novel colloidal carriers designed and targeted against TB. Colloidal carriers employing drugs alone or in combination targeted towards the site of action could lead to reduction in duration of conventional treatment, higher patient fulfillment, and prevention of antitubercular drug resistance or toxicity.
-
Sanzhakov M. A., Prozorovskyi V. N., Ipatova O. M., Tikhonova E. G., Medvedeva N. V., Torkhovskaya T. I., The rifampicin drug delivery system based on phospholipid nanoparticles, Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 8, 2, 2014. Crossref
-
Shiehzadeh Farideh, Hadizadeh Farzin, Mohammadpour Amirhoushang, Aryan Ehsan, Gholami Leila, Tafaghodi Mohsen, Streptomycin sulfate dry powder inhalers for the new tuberculosis treatment schedule, Journal of Drug Delivery Science and Technology, 52, 2019. Crossref
-
Gupta Swati, Pathak Yashwant, Gupta Manish K., Vyas Suresh P., RETRACTED ARTICLE: Nanoscale drug delivery strategies for therapy of ovarian cancer: conventional vs targeted, Artificial Cells, Nanomedicine, and Biotechnology, 47, 1, 2019. Crossref
-
Sanzhakov M.A., Prozorovskyi V.N., Ipatova O.M., Tikhonova E.G., Medvedeva N.V., Torkhovskaya T.I., Drug delivery system on the base of phospholipid nanoparticles for rifampicin, Biomeditsinskaya Khimiya, 59, 5, 2013. Crossref
-
Măruţescu Luminiţa, Frăţiean Diana, Chifiriuc Mariana Carmen, Nanomedicine progress in prevention, detection, and treatment of tuberculosis, in Nanomaterials for Drug Delivery and Therapy, 2019. Crossref
-
Hasija Rahul, Chaurasia Sundeep, Gupta Swati, Formulation design, optimization and in vivo evaluation of oral co-encapsulated resveratrol-humic acid colloidal polymeric nanocarriers, Pharmaceutical Development and Technology, 26, 9, 2021. Crossref
-
Selvakani Prabakaran, Murugan Sumathra, Rajan Mariappan, The pulmonary administration route: Advantages and challenges, in A Mechanistic Approach to Medicines for Tuberculosis Nanotherapy, 2021. Crossref
-
Maurya Priyanka, Saklani Ravi, Singh Samipta, Nisha Raquibun, Pal Ravi Raj, Mishra Nidhi, Singh Priya, Kumar Abhiram, Chourasia Manish K., Saraf Shubhini A., Appraisal of fluoroquinolone-loaded carubinose-linked hybrid nanoparticles for glycotargeting to alveolar macrophages, Drug Delivery and Translational Research, 12, 7, 2022. Crossref
-
Rath Goutam, Pradhan Deepak, Ghosh Goutam, Goyal Amit K., Challenges and Opportunities of Nanotechnological based Approach for the Treatment of Tuberculosis, Current Pharmaceutical Design, 27, 17, 2021. Crossref
-
Prabhu Pratiksha, Fernandes Trinette, Damani Mansi, Chaubey Pramila, Narayanan Shridhar, Sawarkar Sujata, 2 Receptor Specific Ligand Conjugated Nanocarriers: An Effective Strategy for Targeted Therapy of Tuberculosis, Current Drug Delivery, 19, 8, 2022. Crossref